Hefei Lifeon Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
Hefei Lifeon Pharmaceutical has been growing earnings at an average annual rate of 12.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 0.7% per year. Hefei Lifeon Pharmaceutical's return on equity is 9.2%, and it has net margins of 11.6%.
Key information
12.8%
Earnings growth rate
5.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 0.7% |
| Return on equity | 9.2% |
| Net Margin | 11.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 05
Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues
Apr 29Recent updates
Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 05Hefei Lifeon Pharmaceutical (SZSE:003020) Has A Somewhat Strained Balance Sheet
Sep 30Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50
May 23Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump
May 22Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues
Apr 29Revenue & Expenses Breakdown
How Hefei Lifeon Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,501 | 174 | 780 | 79 |
| 30 Jun 24 | 1,402 | 173 | 715 | 79 |
| 31 Mar 24 | 1,423 | 191 | 640 | 96 |
| 31 Dec 23 | 1,901 | 227 | 663 | 85 |
| 30 Sep 23 | 2,210 | 210 | 644 | 81 |
| 30 Jun 23 | 2,618 | 242 | 705 | 85 |
| 31 Mar 23 | 2,763 | 228 | 700 | 73 |
| 01 Jan 23 | 2,579 | 209 | 676 | 74 |
| 30 Sep 22 | 2,503 | 217 | 674 | 75 |
| 30 Jun 22 | 2,429 | 187 | 675 | 68 |
| 31 Mar 22 | 2,353 | 178 | 671 | 67 |
| 31 Dec 21 | 2,273 | 172 | 650 | 66 |
| 30 Sep 21 | 2,183 | 161 | 609 | 52 |
| 30 Jun 21 | 2,076 | 153 | 556 | 54 |
| 31 Mar 21 | 1,991 | 148 | 494 | 51 |
| 31 Dec 20 | 1,894 | 135 | 433 | 43 |
| 30 Sep 20 | 1,809 | 127 | 408 | 47 |
| 30 Jun 20 | 1,758 | 120 | 384 | 45 |
| 31 Mar 20 | 1,711 | 109 | 373 | 36 |
| 31 Dec 19 | 1,650 | 105 | 363 | 37 |
| 31 Dec 18 | 1,425 | 92 | 295 | 24 |
| 31 Dec 17 | 1,167 | 77 | 144 | 18 |
| 31 Dec 16 | 1,028 | 67 | 93 | 12 |
| 31 Dec 14 | 962 | 54 | 107 | 0 |
| 31 Dec 13 | 878 | 47 | 108 | 0 |
Quality Earnings: 003020 has high quality earnings.
Growing Profit Margin: 003020's current net profit margins (11.6%) are higher than last year (9.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 003020's earnings have grown by 12.8% per year over the past 5 years.
Accelerating Growth: 003020's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 003020 had negative earnings growth (-17%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 003020's Return on Equity (9.2%) is considered low.